Liquidia Corp: insider trades · United States · SEC (Form 4)

About Liquidia Corp

Liquidia Corp (NASDAQ: LQDA) is a U.S.-based biopharmaceutical company listed on the NASDAQ in the United States, focused on difficult-to-treat respiratory and vascular diseases. For investors, the key takeaway is that Liquidia is no longer a purely pre-commercial research story: it has crossed into commercialization with an approved and marketed product, while still retaining a development pipeline built around its proprietary PRINT® technology, designed to engineer precise particles. That technology remains central to the equity case because it supports formulation, drug delivery, and potentially broader future applications. The company’s roots trace back to Liquidia Technologies, its wholly owned subsidiary and predecessor for SEC reporting purposes, before the business evolved into a commercial specialty biopharma platform. Liquidia is headquartered in Morrisville, North Carolina, in the Research Triangle area, one of the most established life-science clusters in the United States. That location provides access to talent, manufacturing and development infrastructure, and a broader ecosystem of scientific partners and service providers. Liquidia’s core business today is anchored by YUTREPIA® (treprostinil) inhalation powder, a therapy approved for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company is developing L606, an investigational extended-release formulation of treprostinil intended for twice-daily administration with a next-generation nebulizer. Liquidia also states that it commercializes generic treprostinil injection for PAH. This combination of a marketed product, a development asset, and a complementary commercial franchise gives the company a more diversified profile than a single-asset biotech, although execution risk remains material. From a competitive standpoint, Liquidia operates in a niche but highly regulated specialty market, where clinical differentiation, device/formulation expertise, and regulatory execution matter more than broad scale. Its competitive edge lies in precision-engineered inhalation therapy and the ability to translate a proprietary particle-engineering platform into real-world commercial uptake. Recent company disclosures indicate that YUTREPIA is gaining traction commercially, with full-year 2025 net product sales of about $148.3 million and roughly $130 million in first-quarter 2026 net product sales, underscoring that the business is now meaningfully commercial. The company has also issued several investor updates and conference participation announcements in spring 2026, and recent Form 4 filings reflect insider transactions, including share sales and award-related activity, which investors should view in context rather than in isolation. Overall, Liquidia is a NASDAQ-listed U.S. healthcare name that sits between a growth-stage specialty pharma company and a commercially established rare-disease player. The story combines a proprietary technology base, a newly scaled commercial product, and a pipeline that could extend the franchise, but it also remains exposed to reimbursement, execution, and competitive risks typical of specialty biopharma.